Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Multiple Myeloma × Doxorubicin × Clear all

Phase

Phase 2 16 Phase 3 13 Phase 1 4 Phase 1/2 3 Phase NA 1 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Breast Neoplasms 3 Neoplasm, Residual 2 Wilms Tumor 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Rhabdomyosarcoma 1 Obesity 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Liver Neoplasms 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Body Weight 1

Interventions

Lenalidomide 9 Dexamethasone 9 Zoledronic Acid 7 Bortezomib 7 Melphalan 4 ixazomib 3 daratumumab 3 tocilizumab 2 pomalidomide 2 carfilzomib 2 Prednisone 2 Filgrastim 2 Cyclophosphamide 2 Calcium Dobesilate 2 zanubrutinib 1 talquetamab 1 pegylated granulocyte colony-stimulating factor 1 montelukast 1 isatuximab 1 ibrutinib 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 apixaban 1 Vaccination 1 Thiotepa 1 Thalidomide 1 Tablets 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02577783 2020-02-05

PDD vs PAD to Treat Initially Diagnosed MM

The First Affiliated Hospital of Soochow University

Phase 4 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡